2024
A randomized controlled trial of efficacy and safety of Fecal Microbiota Transplant for preventing recurrent Clostridioides difficile infection
Drekonja D, Shaukat A, Huang Y, Zhang J, Reinink A, Nugent S, Dominitz J, Davis-Karim A, Gerding D, Kyriakides T. A randomized controlled trial of efficacy and safety of Fecal Microbiota Transplant for preventing recurrent Clostridioides difficile infection. Clinical Infectious Diseases 2024, ciae467. PMID: 39271107, DOI: 10.1093/cid/ciae467.Peer-Reviewed Original ResearchCDI recurrenceClostridioides difficile infectionFecal microbiota transplantationRecurrent Clostridioides difficile infectionAdverse eventsPreventing recurrent Clostridioides difficile infectionOral fecal microbiota transplantationMicrobiota transplantationCause of healthcare-associated infectionsSafety of fecal microbiota transplantationDouble-blind clinical trialTrials of efficacyHealthcare-associated infectionsStatistically significant differenceRandomized controlled trialsClinical recurrenceUnformed stoolsPlacebo armPlacebo capsulesPrimary endpointDifficile infectionRecurrent diarrheaAntibiotic treatmentVeterans Health Administration systemClinical trials
2011
Results of Antiretroviral Treatment Interruption and Intensification in Advanced Multi-Drug Resistant HIV Infection from the OPTIMA Trial
Holodniy M, Brown ST, Cameron DW, Kyriakides TC, Angus B, Babiker A, Singer J, Owens DK, Anis A, Goodall R, Hudson F, Piaseczny M, Russo J, Schechter M, Deyton L, Darbyshire J, . Results of Antiretroviral Treatment Interruption and Intensification in Advanced Multi-Drug Resistant HIV Infection from the OPTIMA Trial. PLOS ONE 2011, 6: e14764. PMID: 21483491, PMCID: PMC3069000, DOI: 10.1371/journal.pone.0014764.Peer-Reviewed Original ResearchConceptsRe-treatment optionsART interruptionHIV infectionPrimary outcomeRetreatment optionsMultidrug resistanceAdvanced HIV diseaseAntiretroviral treatment interruptionARV treatment failurePrior AIDS diagnosisResistant HIV InfectionMedian CD4 countPrimary composite outcomeSerious adverse eventsMean viral loadBest medical managementOPTIMA trialCD4 countOpen labelTreatment interruptionAdverse eventsComposite outcomeFirst AIDSHIV diseaseAntiretroviral treatment
2009
Quality of Life of Patients With Advanced HIV/AIDS: Measuring the Impact of Both AIDS-Defining Events and Non-AIDS Serious Adverse Events
Anis AH, Nosyk B, Sun H, Guh DP, Bansback N, Li X, Barnett PG, Joyce V, Swanson KM, Kyriakides TC, Holodniy M, Cameron DW, Brown ST. Quality of Life of Patients With Advanced HIV/AIDS: Measuring the Impact of Both AIDS-Defining Events and Non-AIDS Serious Adverse Events. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2009, 51: 631-639. PMID: 19430303, DOI: 10.1097/qai.0b013e3181a4f00d.Peer-Reviewed Original ResearchConceptsSerious adverse eventsLate-stage HIV/AIDSAdvanced HIV/AIDSHIV/AIDSAdverse eventsMedical Outcomes Study HIV Health SurveyMental health summary scoresEffect of ADEMultidrug-resistant HIVHealth-related qualityHealth summary scoresQuality of lifePatients' HRQOLMultivariate linear regression modelRegular followHRQOL measuresTreatment strategiesEQ-5DHealth SurveyHRQoLImmune diseasesSummary scoresPatientsStudy sample populationAIDS